Investment
Karolinska Development AB has invested in EvoStem Finland Oy, enabling the company to advance its portfolio of stem cell and other tissue engineering-based treatments for veterinary and human use.
In 2007 EvoStem introduced its first product, TendoStem, to the market in Scandinavia. TendoStem is a stem cell-based treatment service for tendon and ligament injuries in horses.
“With this investment, we will speed up our international growth and product development projects,” said Minna Leppänen, CEO of EvoStem. “The investment of Karolinska Development and its strong, long-time commitment gives us a solid ground for a long-term development of our company.”
“EvoStem has demonstrated that stem cell therapy for regenerative medicine is ready for the market. [This investment] strengthens our presence in the cell therapy area where we expect strong growth and medical progress,” said Hans-Peter Ekre, Investment Manager, Karolinska Development AB.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
